Quest Diagnostics (DGX)
173.30
-1.71 (-0.98%)
Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services
The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management.

The research firm noted that post-pandemic utilization rates have remained high, and Labcorp is positioned to capitalize on this trend through its core diagnostics business.
Via Stocktwits · March 5, 2025

Via Benzinga · March 4, 2025

Via Benzinga · March 4, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · March 3, 2025

Diagnostic imaging company RadNet (NASDAQRDNT)
will be reporting results tomorrow after market hours. Here’s what to look for.
Via StockStory · February 26, 2025

Via Benzinga · January 31, 2025

Quest has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13% to $170.50 per share while the index has gained 9.4%.
Via StockStory · February 20, 2025

Oncology (cancer) diagnostics company NeoGenomics (NASDAQNEO)
will be reporting results tomorrow morning. Here’s what to look for.
Via StockStory · February 17, 2025

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.
Via Benzinga · February 12, 2025

Healthcare diagnostics company Labcorp Holdings (NYSELH)
will be reporting earnings tomorrow before the bell. Here’s what to look for.
Via StockStory · February 5, 2025

Health care services provider Encompass Health (NYSEEHC)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
Via StockStory · February 5, 2025

Healthcare diagnostics company Quest Diagnostics (NYSEDGX) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 14.6% year on year to $2.62 billion. Its non-GAAP profit of $2.23 per share was 2.1% above analysts’ consensus estimates.
Via StockStory · February 4, 2025

Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024.
Via The Motley Fool · January 30, 2025

Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.
Via Stocktwits · January 30, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.
Via Chartmill · January 30, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · January 30, 2025

Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share.
Via Benzinga · January 30, 2025

Via Benzinga · January 30, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · January 24, 2025

Via Benzinga · January 6, 2025

Via Benzinga · January 6, 2025